Subcutaneous · Amylin analog
KBP-336
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
1
Ongoing
1
Recruiting
1
Completed
0
Sites
20
Countries
6
Endpoints
15
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
5
Patient-reported / QoL
5
Other clinical outcomes
4
Safety / tolerability / PK
1
Top 20 metrics across this asset's endpoints
WOMAC painOther clin.
2
Body weight, % changeWeight
1
WOMAC functionOther clin.
1
≥15% weight-loss respondersWeight
1
PGI, changePRO/QoL
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06833749Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | GLP-1 / incretin class catch-all, KBP-336 Obesity / overweight, Osteoarthritis, Pain | BMI ≥30 | Ph 2 | Recruiting | 20 | Nov 2026 | - |
Showing 1-1 of 1 trials